Irlanda - inglés - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 1000 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 500 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 250 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.

Israel - inglés - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - inglés - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - inglés - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Malta - inglés - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu - antihemorrhagics

Malta - inglés - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu/ml - antihemorrhagics

Malta - inglés - Medicines Authority

biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 100 iu/ml - antihemorrhagics

Estados Unidos - inglés - NLM (National Library of Medicine)

grifols usa, llc - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 500 [iu] in 10 ml - alphanine sd is indicated for the prevention and control of bleeding in patients with factor ix deficiency due to hemophilia b. alphanine sd contains low, non-therapeutic levels of factors ii, vii, and x, and, therefore, is not indicated for the treatment of factor ii, vii or x deficiencies. this product is also not indicated for the reversal of coumarin anticoagulant-induced hemorrhage, nor in the treatment of hemophilia a patients with inhibitors to factor viii. none known.